Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
The leading peer-reviewed journal in its field, focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids. Comprehensive coverage includes oligonucleotides; RNAi: siRNAs, shRNAs, and miRNAs; aptamers; RNA nanoparticles; gene modification with oligos; antisense applications; nucleoside and nucleotide analogs; peptide nucleic acids; ribozymes; and DNA-modified gene therapy.
Manuscripts must be submitted online using the following URL: http://mc.manuscriptcentral.com/nucleicacidtherapeut
PLEASE READ ALL THE INSTRUCTIONS TO AUTHORS BEFORE SUBMITTING.
Preparation of Manuscript. Manuscripts should be submitted double-spaced. Leave ample margins on both sides, top and bottom.
Be prepared to give the title of the article, name(s) of the author(s) and institutional affiliation(s), and supply a running title of about 45 characters. You also will be required to supply an abstract of about 200 words, stating the aims, results, and conclusions drawn from the study. This should be followed by the Introduction, Materials and Methods, Results, Discussion, Acknowledgments, references, tables, figures, and figure legends. Begin each of these sections on a separate page. We require an e-mail address for each author listed on your article. Authors should review the style and clarity of their manuscripts with colleagues before submission, especially if English is not their native language, to ensure clear grammatical English usage. The editors welcome suggestions concerning potential reviewers. We encourage authors to report all of the oligonucleotides or constructs that were studied, not just those that gave the “best” result. Authors should also note the editorial policy of this journal, as described in C.A. Stein and A. Krieg, “Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides,” Antisense and Nucleic Acid Drug Development, 1994, (4), 67–69. All manuscripts that claim antisense efficacy must, in addition to the antisense oligodeoxynucleotide construct, include at least two control oligodeoxynucleotides. The sequences of the two controls are to be decided by the authors. Manuscripts that do not include at least two controls will be returned without review.
Brief Communications may be submitted to report negative findings, useful techniques, or unusual artifacts, or to present studies that are interesting but not definitive enough to warrant publication as a full-length manuscript. In a Brief Communication, the Results and Discussion sections may be combined, the Abstract should be limited to about 150 words, and there should be no more than three figures or tables.
All authors of a manuscript must have agreed to its submission and are equally responsible for its content. By submitting a manuscript, the authors guarantee that the manuscript, or one substantially the same, was not published previously and is not being considered or published elsewhere. A preliminary disclosure of research findings published in abstract form as an adjunct to a meeting is not considered prior publication.
Copies of “in press” and “submitted” manuscripts that are important for consideration of the present manuscript should be enclosed to facilitate the review process. Include written permission to cite any personal communications and preprints.
Every effort will be made to complete the review process within 4–6 weeks of receipt of the manuscript.
Letters to the Editor(s): Letters to the Editor(s) are welcomed, but with a 500 word limit and no more than (1) table OR figure, and with a maximum of four (4) references.
Tables and Illustrations. Use arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.
Please observe the following guidelines when submitting art:
• Do not include any illustrations as part of your text file.
• Do not prepare any figures in Word as they are not workable.
• Line illustrations must be submitted at 1200 DPI.
• Halftones and color photos should be submitted at a minimum of 300 DPI.
• Adobe is the preferred software. Avoid submitting PowerPoint files.
• Save art as either TIFF or EPS files. Avoid submitting JPEG files.
• Color art must be saved as CYMK, not RGB.
The Journal will publish color photographs, but the author must subsidize the cost of the color printing. For further details, contact the Publisher.
When naming your figure files, please label them with your manuscript number, followed by a period (.), and then list the figure number. Ex: MET-2008-0123.Fig1.
For submissions containing Western blot images, the original gels from which the blots were derived must be uploaded as "Supplemental Material - For Review Only" under the file designation “Original Whole Cell(s) for Western Blots.” These files would be used for peer review purposes only.
Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
If no conflicts exist, the authors must state “No competing financial interests exist."
Figure legends: These must be double-spaced in a separate word file uploaded after the main document.
References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper. Authors are responsible for the accuracy of all literature citations. Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text. References should be listed numerically in the text in the order of appearance as parenthesized consecutive numbers, e.g., [1,2]. Where there are more than two references, the citation should appear as hyphenated numbers, e.g., [1–3]. References should be typed double-spaced in numerical order of citation, with all authors listed. Abbreviations of journals should conform to those used in Medline. The following formats must be used:
Sugita H and S Takeda. (2010). Progress in muscular dystrophy research with special emphasis on gene therapy. Proc Jpn Acad Ser 86:748–756.
Malerba A, L Boldrin and G Dickson. (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 21:293–298.
Aartsma-Rus A, I Fokkema, JJ Verschuuren, HB Ginjaar, JCT van Deutekom, GJB van Ommen and JT den Dunnen. (2009). Applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293–299.
Gerwitz AM, ed. Nucleic Acid Therapeutics in Cancer (Cancer Drug Discovery and Development). (2004). Humana Press, New York, NY.
Chapter in a Book:
Rogers FA, Glazer PM. Targeted genome modification via triple helix formation. In: Nucleic Acid Therapeutics in Cancer (Cancer Drug Discovery and Development). Gerwitz AM, ed. (2004). Humana Press, New York, NY; pp. 27-44.
Website: (Provide these elements, with the following punctuation):
Authors [last name, first/middle initials; if available]. Title of article on website. Website address. Last accessed date.
References: References may be made to published work and articles in press. Reference citations are not permitted in the abstract of a article. Authors are responsible for the accuracy of all literature citations. Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text. References should be listed numerically in the text in the order of appearance as consecutive numbers in brackets, e.g., [1,2]. Where there are more than two references, the citation should appear as hyphenated numbers, e.g., [1–3]. References should be typed double-spaced in numerical order of citation, listing all authors up to 11 - if over 11, list the first 9 and then et al. Abbreviations of journals should conform to those used in MEDLINE. The following formats must be used:
1. Davis ME, ZG Chen and DM Shin. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
2. Davis ME, JE Zuckerman, CHJ choi, D Seligson, A tolcher, CA Alabi, Y Yen, JD Heidel and A. Ribas, (2010). Evedence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070.
Sambrook J, EF Fritsch and T Maniatis, eds. Molecular cloning, 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Sring Harbor, NY.
1. Zhang D. (1993) Synthetic oligonucleotides for antisense applicatons. In: Horizons in Antisense Investigations. L Wu and ME Davis, eds. Springer-Verlag, Heidelberg, pp 425-440.
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."
FOR HUMAN RESEARCH and ANIMAL STUDIES
Provide sufficient information to permit both reproduction of the results by other investigators and appropriate critical evaluation of the procedures used.
For human research, authors must ensure that studies are performed according to the amended Declaration of Helsinki. Authors should indicate institutional review board approval of the protocol used. Include a statement confirming that all patients gave written informed consent. Where applicable, statement must also be made of approval for human pluripotent stem cell use.
Similarly, all animal research must conform to the respective national guidelines and authors should indicate institutional review board approval of the protocol used.
Permissions. The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote of a reprinted table, or of the legend of a reprinted figure, should read, “reprinted by permission from Doe et al.” and list the appropriate reference. All permission listings must be shown in the manuscript; they cannot be entered on proofs.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
Nucleic Acid Therapeutics is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.